For adults with type 2 diabetes and obesity, Ozempics ability to address both conditions simultaneously makes it a compelling choice, though the weight loss drug benefits come with more gastrointestinal side effects during the initial weeks
Other ASCO-presented research found that people with stage I, II, or III lung, breast, colorectal, or liver cancer who took a GLP-1 drug were less likely to progress to stage IV disease than those who did not take one
Ozempic (semaglutide), approved by the FDA in 2017, represents the newer class of GLP-1 receptor agonists that have transformed diabetes care and weight management
We took an initial observation in patients, then expanded this observation in animal models, generated a hypothesis of MR as a possible new target, selected a candidate molecule with spironolactone, tested it in animals, then did the big data science and now were going back to the clinic. Using the same approach, Dr